ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2020

9:00AM-11:00AM: Abstract Number: 1906

Hsp90 Inhibition Effectively Prevents Progression of Dermal Fibrosis and Induces Regression of Established Bleomycin-Induced Dermal Fibrosis

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1844

Hydroxychloroquine and QTc Prolongation in a Cohort of SLE Patients

SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1833

Hydroxychloroquine and Vitamin D Both Reduce Proteinuria in SLE

SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1678

Hydroxychloroquine Blood Levels Predicts 6-Months Disease Activity in Juvenile Lupus Nephritis

Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

9:00AM-11:00AM: Abstract Number: 1594

Hydroxychloroquine Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution

Measures & Measurement of Healthcare Quality Poster

9:00AM-11:00AM: Abstract Number: 1848

Identification of Native and Citrullinated Autoantibodies to Psoriasis Related-antigen PsoP27 in Synovial Fluids of Patients with Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1849

Identification of New Associations Between Psoriatic Arthritis and the Gut Microbiota. the Mi-PART, a Phenomic Study

Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1865

Identification of Parameters Associated with a Diagnostic Delay in Axial Spondyloarthritis:Results from the European Map of Axial Spondyloarthritis (EMAS)

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

9:00AM-11:00AM: Abstract Number: 1704

Identifying Primary Care Clinician Knowledge Gaps and Needs in Rheumatologic Care for Rural Veterans

Professional Education Poster

9:00AM-11:00AM: Abstract Number: 1671

Identifying Rare Genetic Variants in Childhood-onset Monogenic Systemic Lupus Erythematosus

Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

9:00AM-11:00AM: Abstract Number: 1798

IgE Anti-dsDNA Antibodies in Systemic Lupus Erythematosus Are Associated with Higher Disease Activity at the Baseline and in Longterm Follow-up

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

9:00AM-11:00AM: Abstract Number: 1818

IgG and IgA Autoantibodies Against L1 ORF1p Expressed in Granulocytes Correlate with Granulocyte Consumption and Disease Activity in Pediatric Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

9:00AM-11:00AM: Abstract Number: 1911

IL-11 Expression in Systemic Sclerosis Pulmonary Fibroblasts Is Mediated by Caspase-1

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1570

Immune Checkpoint Inhibitor Treatment in Cancer: Immunomodulator Use and Evaluation by Rheumatology

Immunological Complications of Therapy Poster

9:00AM-11:00AM: Abstract Number: 1577

Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis

Immunological Complications of Therapy Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].